Skip to content

Study on Recurrence after Curative Surgery for Primary Liver Cancer

Study on Recurrence after Curative Surgery for Primary Liver Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093776
Enrollment
Unknown
Registered
2024-12-11
Start date
2024-06-17
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary liver cancer

Interventions

Observation group:None

Sponsors

The Fifth Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old; 2. Diagnosed with primary liver cancer according to the Diagnostic and Treatment Criteria for Primary Liver Cancer (2024 edition) 3. Radical treatment is available in multidisciplinary consultation; 4. Patients with BCLC staging of A, B, Child-Pugh score A or B and ECOG PS score 0~2; 5. Patients voluntarily participated in this clinical study, understood and signed the informed consent, complied with the study requirements and had good compliance.

Exclusion criteria

Exclusion criteria: 1. Patients with residual or suspected residual tumor 1 month after radical surgery 2. Patients with other malignant tumors at the same time; 3. Patients with severe coagulation dysfunction or severe thrombocytopenic purpura; 4. Patients with active infection of HIV, EBV, cytomegalovirus, syphilis, tuberculosis, etc. at the time of enrollment; 5. Patients with combined refractory ascites or severe portal hypertension; 6. Patients with combined severe cardiac, pulmonary, renal and other systemic insufficiency; 7. Patients with psychiatric disorders with an anticipated risk of treatment interruption, failure of efficacy assessment, inability to understand informed consent and poor compliance; 8. Pregnant women with combined autoimmune diseases.

Design outcomes

Primary

MeasureTime frame
Recurrence Free Survival;

Secondary

MeasureTime frame
Overall Survival;Adverse events;

Countries

China

Contacts

Public ContactZhen Zeng

The Fifth Medical Center of Chinese PLA General Hospital

zengzhen1970@sina.com+86 131 2677 8822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026